Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a Healthcare company (Biotechnology) with a market capitalization of $808M. The Maz Rating grades it against the other companies in its sector.
Rigel Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $42.92, Rigel Pharmaceuticals, Inc. trades at 2.5x trailing earnings, 2.8x sales and 1.8x book value, with an EV/EBITDA of 9.2. Over the last twelve months it generated about $291M of revenue and $320M of net income. It runs a gross margin of 89.6%, an operating margin of 26.3% and a net margin of 106.6%. It shows return on equity of 73.9%, return on invested capital of 16.7% and a free cash flow yield of 11.1%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 2.39. Over the past 52 weeks the share price ranged from $24.95 to $52.61, with a beta of 1.24.
Rigel Pharmaceuticals, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 8 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.